Biondo Investment Advisors Llc decreased its stake in Regeneron Pharmaceuticals (REGN) by 31.49% based on its latest 2018Q4 regulatory filing with the SEC. Biondo Investment Advisors Llc sold 8,160 shares as the company’s stock rose 19.30% with the market. The institutional investor held 17,752 shares of the health care company at the end of 2018Q4, valued at $6.63M, down from 25,912 at the end of the previous reported quarter. Biondo Investment Advisors Llc who had been investing in Regeneron Pharmaceuticals for a number of months, seems to be less bullish one the $33.24B market cap company. The stock decreased 2.69% or $8.41 during the last trading session, reaching $304.45. About 938,608 shares traded or 21.15% up from the average. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 34.82% since May 13, 2018 and is uptrending. It has outperformed by 30.45% the S&P500. Some Historical REGN News: 19/03/2018 – NOVARTIS SEEKS COMPENSATORY AND TRIPLE DAMAGES FOR RENEGERON’S ALLEGED WILLFUL PATENT INFRINGEMENT, IN A LAWSUIT FILED WITH THE U.S. DISTRICT COURT IN MANHATTAN; 21/05/2018 – New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Sever; 21/03/2018 – Regeneron Genetics Center® Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease; 21/03/2018 – ALNYLAM PHARMACEUTICALS INC – REGENERON WILL CONTRIBUTE RESEARCH ON HEPATOCYTE-EXPRESSED, GENETICALLY-VALIDATED HSD17B13 TARGET; 11/05/2018 – Bayer: Second Indication for Eylea to Be Approved in China; 24/04/2018 – Biotech stars Schleifer and Yancopoulos share $52M in 2017 compensation, even though Regeneron’s share price swooned Plus $264M for Yancopoulos in vested value; 19/03/2018 – REGENERON PHARMA-PHASE 3 TRIAL EVALUATING EYLEA INJECTION IN MODERATELY SEVERE TO SEVERE NON-PROLIFERATIVE DIABETIC RETINOPATHY MET PRIMARY ENDPOINT; 11/05/2018 – Bayer: Eylea Treats Visual Impairment From Macular Degeneration; 19/03/2018 – REGENERON PHARMACEUTICALS – EXPECT U.S. REGULATORY SUBMISSION FOR DIABETIC RETINOPATHY LATER THIS YEAR; 16/05/2018 – DUPIXENT TRIAL MEETS PRIMARY, SECONDARY ENDPOINTS
Gagnon Advisors Llc increased its stake in Navigator Holdings Ltd (NVGS) by 40.06% based on its latest 2018Q4 regulatory filing with the SEC. Gagnon Advisors Llc bought 152,347 shares as the company’s stock declined 10.98% while stock markets rallied. The hedge fund held 532,674 shares of the marine transportation company at the end of 2018Q4, valued at $5.01 million, up from 380,327 at the end of the previous reported quarter. Gagnon Advisors Llc who had been investing in Navigator Holdings Ltd for a number of months, seems to be bullish on the $597.31 million market cap company. The stock decreased 3.14% or $0.35 during the last trading session, reaching $10.73. About 34,985 shares traded. Navigator Holdings Ltd. (NYSE:NVGS) has declined 1.35% since May 13, 2018 and is downtrending. It has underperformed by 5.72% the S&P500.
Investors sentiment decreased to 1.13 in 2018 Q4. Its down 0.01, from 1.14 in 2018Q3. It fall, as 52 investors sold REGN shares while 165 reduced holdings. 72 funds opened positions while 174 raised stakes. 77.33 million shares or 9.82% more from 70.41 million shares in 2018Q3 were reported. Mitsubishi Ufj Tru & Banking holds 0.1% or 66,163 shares. Deutsche Natl Bank Ag, Germany-based fund reported 490,086 shares. Premier Asset Management Limited Com has invested 3.36% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Landscape Cap Mgmt Lc has 2,061 shares for 0.06% of their portfolio. Gabelli Funds Ltd Limited Liability Company has 2,100 shares for 0.01% of their portfolio. Earnest Ptnrs Ltd Llc reported 36 shares. Oakworth Cap owns 0% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 42 shares. Blume Mngmt has invested 0.02% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Nuwave Investment Management Ltd Liability invested in 24 shares. Blackrock Inc invested in 0.11% or 5.93 million shares. Cypress Asset Inc Tx has 1,973 shares. Temasek (Private) Ltd invested in 0.32% or 126,351 shares. The Tennessee-based State Of Tennessee Treasury Department has invested 0.13% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Lombard Odier Asset Management (Europe) invested in 0.03% or 882 shares. Great West Life Assurance Can has 0.07% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 65,965 shares.
More notable recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news were published by: Nasdaq.com which released: “Is Alnylam Pharmaceuticals a Buy Now? – Nasdaq” on April 16, 2019, also Nasdaq.com with their article: “April 26th Options Now Available For Regeneron Pharmaceuticals (REGN) – Nasdaq” published on March 11, 2019, Nasdaq.com published: “Noteworthy Thursday Option Activity: FLR, ALGN, REGN – Nasdaq” on May 02, 2019. More interesting news about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: Nasdaq.com and their article: “REGN Crosses Above Average Analyst Target – Nasdaq” published on January 11, 2019 as well as Nasdaq.com‘s news article titled: “Health Care Sector Update for 05/07/2019: PINC,CPRX,HSIC,REGN,SNY – Nasdaq” with publication date: May 07, 2019.
Biondo Investment Advisors Llc, which manages about $423.40M and $331.26M US Long portfolio, upped its stake in Svb Finl Group (NASDAQ:SIVB) by 8,095 shares to 9,645 shares, valued at $1.83 million in 2018Q4, according to the filing. It also increased its holding in Exxon Mobil Corp (NYSE:XOM) by 53,760 shares in the quarter, for a total of 60,652 shares, and has risen its stake in Align Technology Inc (NASDAQ:ALGN).
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.